Copertina

Low‐Dose Golidocitinib for Triple‐Mutant (JAK1/STAT3/TET2) ITLPD‐GI After DLBCL Remission

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Wenwen Wang, Zhengying Ruan, Jianlin Chen
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Hematological Oncology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

169 | PHOSPHO‐STAT3 EXPRESSION AND JAK/STAT PATHWAY ACTIVATION ACROSS GENETIC SUBTYPES OF DIFFUSE LARGE B‐CELL LYMPHOMA
di: A. A. Pomares, et al.
Pubblicazione: (2025)

479 | DLBCL‐ASSOCIATED PIM1 MUTATION DRIVES ANXA2 RELOCATION ON THE MEMBRANE AND PROMOTES LYMPHOMAGENESIS
di: Y. Lu, et al.
Pubblicazione: (2025)

394 | RUXOLITINIB TARGETS STAT1‐STAT3 COOPERATIVELY IN LARGE GRANULAR LYMPHOCYTIC LEUKEMIA
di: A. Marouf, et al.
Pubblicazione: (2025)

UCLI01 | ADVANCES IN DLBCL MANAGEMENT: HIGHLIGHTS FROM CHINA
di: D. Zhao
Pubblicazione: (2025)

Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study
di: Alessandra Iurlo, et al.
Pubblicazione: (2025)

651 | UTILITY OF GERIATRIC ASSESSMENT TOOLS TO PREDICT CHEMOTOXICITY AMONGST ELDERLY PATIENTS WITH DLBCL
di: L. Poon, et al.
Pubblicazione: (2025)

494 | IMMUNOPROFILING OF THE TUMOR MICROENVIRONMENT IN DLBCL USING MULTIPLEXED IMMUNOFLUORESCENCE AND QuPath ANALYSIS
di: J. Hashemi, et al.
Pubblicazione: (2025)

890 | DYNAMIC VARYING IN SECONDARY PRIMARY MALIGNANCIES IN DLBCL SURVIVORS: A COMPARATIVE STUDY OF THE PRE‐ AND POST‐RITUXIMAB ERAS
di: W. Lu, et al.
Pubblicazione: (2025)

LBA1 | THE BENEFIT OF POLA‐R‐CHP IN DLBclass‐DEFINED MOLECULAR SUBSETS OF NEWLY DIAGNOSED DLBCL IN THE POLARIX TRIAL
di: E. Calabretta, et al.
Pubblicazione: (2025)

477 | LONGITUDINAL MULTI‐OMICS INVESTIGATION IN IBRUTINIB‐BORTEZOMIB‐R‐CHOP‐TREATED DLBCL PATIENTS
di: S. Denker, et al.
Pubblicazione: (2025)

650 | EFFICACY OF POLA‐R‐CHP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL: A RETROSPECTIVE ANALYSIS OF REAL‐WORLD DATA
di: S. Yang, et al.
Pubblicazione: (2025)

410 | EVALUATION OF AN ARTIFICIAL INTELLIGENCE METHOD FOR LESION SEGMENTATION OF BASELINE FDG PET STUDIES OF DLBCL PATIENTS
di: M. C. Ferrandez, et al.
Pubblicazione: (2025)

508 | BAYESIAN PENALIZED LIKELIHOOD RECONSTRUCTION ALGORITHM RESULTS IN SIMILAR PROGNOSTIC MARKERS ON FDG PET/CT IN DLBCL
di: H. L. Huang, et al.
Pubblicazione: (2025)

Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma—A Regression Analysis of Dose‐Response
di: Lotte Nygård, et al.
Pubblicazione: (2025)

294 | CLINICAL PRACTICE PATTERN AND OUTCOMES IN DLBCL WITH DISTINCT GENETIC SUBTYPES: A LARGE‐SCALE REAL‐WORLD STUDY FROM CHINA
di: P. Xu, et al.
Pubblicazione: (2025)

655 | POLA‐R‐CHP PERFORMED WELL IN POLARIX TRIAL‐INELIGIBLE AND LOW RISK (IPI 0–1) PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: A PROSPECTIVE OBSERVATIONAL STUDY
di: Y. Ren, et al.
Pubblicazione: (2025)

285 | EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN, ZANUBRUTINIB AND RITUXIMAB IN UNTREATED ELDERLY AND FRAIL DLBCL PATIENTS: A PROSPECTIVE PHASE 2 CLINICAL TRIAL
di: Y. Ren, et al.
Pubblicazione: (2025)

689 | HOW TO OPTIMIZE THE USE OF HIGH‐COST THERAPIES IN DLBCL: A COLLABORATIVE OBSERVATIONAL STUDY BY THE URUGUAYAN LYMPHOMA GROUP
di: M. V. Irigoin, et al.
Pubblicazione: (2025)

295 | EARLY MORTALITY DLBCL PREDICTION WITH AN ENHANCED R‐IPI SCORE DEVELOPED USING AN ENSEMBLE MACHINE LEARNING MODEL
di: A. Muthiah, et al.
Pubblicazione: (2025)

158 | EPCORE DLBCL‐3: FIXED‐DURATION EPCORITAMAB MONOTHERAPY IN OLDER (≥ 75 Y), ANTHRACYCLINE‐INELIGIBLE PATIENTS WITH PREVIOUSLY UNTREATED LARGE B‐CELL LYMPHOMA (LBCL)
di: D. Belada, et al.
Pubblicazione: (2025)

161 | OUTCOMES OF GLOFITAMAB AND EPCORITAMAB IN R/R DLBCL ELDERLY PATIENTS: A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUM
di: S. K. Thiruvengadam, et al.
Pubblicazione: (2025)

75 | POPULATION‐WIDE INTRODUCTION OF DOSE‐ADJUSTED EPOCH‐R IN HIGH‐GRADE B‐CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS WITH DLBCL MORPHOLOGY
di: W. Alduaij, et al.
Pubblicazione: (2025)

186 | AN IN VIVO PIGGYBAC INSERTIONAL MUTAGENESIS SCREEN TO SEARCH FOR MODIFIERS OF Myd88L265P‐DRIVEN DLBCL LYMPHOMAGENESIS
di: S. Höfmann, et al.
Pubblicazione: (2025)

6 | FEASIBILITY OF CTDNA AND PET GUIDED THERAPY IN UNTREATED DLBCL. PRELIMINARY RESULTS OF THE SAKK 38/19 PHASE II TRIAL
di: A. Stathis, et al.
Pubblicazione: (2025)

818 | INTERIM ANALYSIS OF POMALIDOMIDE PLUS RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN RELAPSED/REFRACTORY DLBCL: A PHASE I/II STUDY (PRIDE STUDY)
di: P. Xu, et al.
Pubblicazione: (2025)

41 | PROSPECTIVE VALIDATION OF END OF TREATMENT ctDNA‐MRD BY PhasED‐Seq IN DLBCL PATIENTS FROM A NATIONAL HOVON TRIAL
di: M. E. Chamuleau, et al.
Pubblicazione: (2025)

282 | DURABLE EFFICACY WITH FIXED‐DURATION EPCORITAMAB + POLATUZUMAB, VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA‐R‐CHP) FOR 1L DLBCL (EPCORE NHL‐5)
di: D. Lavie, et al.
Pubblicazione: (2025)

642 | REAL‐WORLD EFFICACY AND SAFETY OF GLOFITAMAB IN CHINESE PATIENTS WITH R/R DLBCL: HIGH RESPONSE RATES IN HIGH‐RISK POPULATIONS
di: Z. Qian, et al.
Pubblicazione: (2025)

121 | INFLUENCE OF HEALTH DISPARITIES (HD) ON CLINICAL OUTCOMES IN PATIENTS (PTS) WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE UNITED STATES
di: A. J. Alencar, et al.
Pubblicazione: (2025)

290 | REAL‐WORLD SAFETY AND EFFICACY OF POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: ANALYSIS OF 500 PATIENTS IN THE POLASTAR STUDY
di: N. Nakamura, et al.
Pubblicazione: (2025)

637 | THE NON‐STANDARD ROLE OF BISPECIFIC ANTIBODIES IN THE TREATMENT ALGORITHM OF RELAPSED/REFRACTORY DLBCL IN COUNTRIES WITHOUT CART. ARGENTINE EXPERIENCE WITH EPCORITAMAB
di: C. Mahuad, et al.
Pubblicazione: (2025)

424 | LONGITUDINAL TARGETED ctDNA ANALYSIS TO ASSESS CD20 and BAFF MUTATIONS IN PATIENTS WITH RELAPSED/REFRACTORY FL OR DLBCL PROGRESSING ON ODRONEXTAMAB IN THE ELM‐2 STUDY
di: D. Tucker, et al.
Pubblicazione: (2025)

854 | SEQUENCING‐GUIDED CHEMOTHERAPY OPTIMIZATION USING REAL‐TIME EVALUATION IN NEWLY DIAGNOSED DLBCL WITH CIRCULATING TUMOR DNA: SHORTEN‐ctDNA
di: H. J. Cherng, et al.
Pubblicazione: (2025)

217 | RICHTER’S TRANSFORMED CHRONIC LYMPHOCYTIC LEUKEMIA OF DIFFUSE LARGE B‐CELL LYMPHOMA—TYPE COMPARED TO DE NOVO DLBCL IN A NATIONWIDE COHORT
di: A. Katsimigas, et al.
Pubblicazione: (2025)

297 | CAUSES OF EXCESS NON‐LYMPHOMA DEATH IN 60,000 PATIENTS WITH DLBCL DIAGNOSED IN ENGLAND, 1997–2020: AN OBSERVATIONAL COHORT STUDY WITH UP TO 25 YEARS FOLLOW‐UP
di: A. Challenger, et al.
Pubblicazione: (2025)

76 | GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (Glofit‐GemOx) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): 2‐YEAR FOLLOW‐UP OF STARGLO
di: J. S. Abramson, et al.
Pubblicazione: (2025)

446 | IMPACT OF RESPONSE TO HOLDING/BRIDGING THERAPY IN SECOND‐LINE DLBCL PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL: A LYSA STUDY FROM THE FRENCH DESCAR‐T REGISTRY
di: A. Capes, et al.
Pubblicazione: (2025)

685 | DRUG PRESCRIPTIONS FOR PERIPHERAL NEUROPATHY AND GASTROINTESTINAL EVENTS IN FIRST‐LINE POLA‐R‐CHP FOR ELDERLY DLBCL PATIENTS INCLUDING THOSE AGED 80+ IN JAPAN
di: Y. Saito, et al.
Pubblicazione: (2025)

665 | REAL WORLD OUTCOMES OF DIFFUSE LARGE B CELL LYMPHOMA IN BRAZIL CONFIRM THE PROGNOSTIC IMPACT OF CELL OF ORIGIN: BRA‐DLBCL MULTICENTER RETROSPECTIVE STUDY.
di: G. F. Perini, et al.
Pubblicazione: (2025)

157 | PET GUIDED OMISSION OF RADIOTHERAPY IN ELDERLY DLBCL PTS WITH LESS FAVOURABLE PROGNOSIS IS SAFE: RESULTS OF 863 PATIENTS TREATED IN THE OPTIMAL > 60 TRIAL OF THE DSHNHL/GLA
di: L. Thurner, et al.
Pubblicazione: (2025)